Rakuten Medical vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 35)
Rakuten Medical logo

Rakuten Medical

NicheLife Sciences & BioTech

Cancer Photoimmunotherapy (Illuminox Platform)

Rakuten Medical is a biotech developing photoimmunotherapy cancer treatment using its Illuminox platform (cetuximab sarotalocan), approved in Japan for head and neck cancer and in clinical trials globally; listed on Tokyo Stock Exchange (TYO: 4707);

AI VisibilityBeta
Overall Score
D35
Category Rank
#143 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
38
Gemini
35

About

Rakuten Medical, Inc. is a biotechnology company founded by Yoshihiro Seto in 2006 (as Aspyrian Therapeutics, renamed Rakuten Medical after acquisition by Rakuten Group) and headquartered in San Diego, California, with primary R&D and commercial operations in Japan. The company is focused on developing cancer treatments using its proprietary photoimmunotherapy (PIT) platform, branded as Illuminox. Photoimmunotherapy combines a targeted antibody conjugated to a photoabsorber dye that, when activated by near-infrared light, selectively destroys cancer cells in the illuminated region while minimizing damage to surrounding healthy tissue — a precision oncology approach distinct from traditional chemotherapy or immunotherapy.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#143
Category Rank
#11
79
AI Consensus
68
stable
Trend
stable
34
ChatGPT
71
38
Perplexity
68
35
Gemini
80
32
Claude
77
29
Grok
69

Key Details

Category
Cancer Photoimmunotherapy (Illuminox Platform)
AI-Enabled Precision Medicine
Tier
Niche
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.